ArticleInfection and drug resistance2019
The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Antimicrobial synergism of silver and zinc oxide nanoparticles with antibiotics against clinical isolate of Cutibacterium acnes.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Metal Oxide Nanocomposites as Next-Generation Antimicrobial Agents Against Oral Cariogenic Pathogens: Mechanistic Actions of Ag-ZnO and Cu-ZnO onMaterials (Basel, Switzerland) · 2026Article
- The Role of Zinc Against Bacterial Infections in Neonates, Children, and Adults: A Scoping Review from the Available Evidence of Randomized Controlled Trials About Zinc Supplementation to New Research Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
- Article
- CLINICALLY RELEVANT METALLIC NANOPARTICLES IN TUBERCULOSIS DIAGNOSIS AND THERAPY.Advanced therapeutics · 2025Article
- Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.Microorganisms · 2025Review
- Microwave-synthesized NiZrO3 Biotech · 2025Article
- Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.Current drug delivery · 2025Review
- Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- Zinc Oxide-Based Nanomaterials for Microbiostatic Activities: A Review.Journal of functional biomaterials · 2024Review
- Zinc oxide nanoparticles mediate bacterial toxicity in Mueller-Hinton Broth via ZnFrontiers in microbiology · 2024Article
- Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.Clinical microbiology reviews · 2023Review
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nanoparticles of Bioactive Metals/Metal Oxides and Their Nanocomposites with Antibacterial Drugs for Biomedical Applications.Materials (Basel, Switzerland) · 2022Review
- Engineering zinc oxide hybrid selenium nanoparticles for synergetic anti-tuberculosis treatment by combining Mycobacterium tuberculosis killings and host cell immunological inhibition.Frontiers in cellular and infection microbiology · 2022Article
- Plant-Based Bimetallic Silver-Zinc Oxide Nanoparticles: A Comprehensive Perspective of Synthesis, Biomedical Applications, and Future Trends.BioMed research international · 2022Review
- Novel mesoporous silica nanocarriers containing gold; a rapid diagnostic tool for tuberculosis.BMC complementary medicine and therapies · 2021Article
- Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-ResistantFrontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNowadays, tuberculosis (TB) is one of the top ten leading causes of mortality worldwide. The emergence of multidrug-resistant (MDR) - and extensively drug-resistant (XDR) - MATERIALS AND
methodsIn this study, Ag, ZnO, and Ag-ZnO NPs were synthesized by the chemical reduction and chemical deposition methods. NPs were characterized using ultraviolet-visible spectroscopy, dynamic light scattering, and transmission electron microscopy. Then, various dilutions of NPs were prepared and their minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against
resultsThe effects of concentrations of 1-128 µg/mL Ag NPs, ZnO NPs, 2Ag: 8ZnO, 8Ag:2ZnO, 3Ag: 7ZnO, 7Ag:3ZnO, and 5Ag:5ZnO on
conclusionTo the best of our knowledge, this is the first study to evaluate the effects of Ag and ZnO NPs against MDR and XDR strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.